Pulmonx Corp stock (US74586W1018): credit line and margin focus keep lung care specialist in the spotlight

Pulmonx Corp is navigating a growth pause with an eye on margins and stronger liquidity. A fresh credit facility and disciplined cost control shape the current narrative around the minimally invasive lung treatment specialist.

Pulmonx Corp, a medical technology company focused on minimally invasive treatments for severe emphysema, remains in focus after its latest quarterly update highlighted improving gross margins, slower top-line growth and a bolstered liquidity position, according to an earnings call summary published on April 30, 2025 by TipRanks as of 04/30/2025.

Management emphasized that Pulmonx closed the quarter with approximately 61.6 million USD in cash, cash equivalents and marketable securities and secured a new 60 million USD interest-only credit facility to support operations and potential growth initiatives, as reported in the same earnings recap by TipRanks as of 04/30/2025.

As of: 17.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Pulmonx Corporation
• Sector/industry: Medical technology, respiratory care
• Headquarters/country: Redwood City, California, United States
• Core markets: United States and selected international healthcare systems
• Key revenue drivers: Zephyr valves and associated lung volume reduction solutions
• Home exchange/listing venue: Nasdaq (ticker: LUNG)
• Trading currency: USD

Pulmonx Corp: core business model

Pulmonx Corp develops and markets minimally invasive devices designed to improve lung function in patients suffering from severe emphysema, a form of chronic obstructive pulmonary disease. Its flagship product, the Zephyr endobronchial valve, aims to reduce lung volume without major surgery, enabling better breathing capacity for suitable patients.

The company works closely with pulmonologists, interventional pulmonology centers and thoracic surgeons to identify and treat patients who meet clinical criteria. Revenue is primarily generated from the sale of devices and related accessories to hospitals and specialized clinics, which then use the technology in reimbursed procedures.

Because emphysema often affects older populations in developed markets, Pulmonx’s addressable market is heavily influenced by demographic trends, diagnostic rates and payer acceptance. The firm’s business model combines initial device adoption with recurring procedure volumes as treatment centers build experience and integrate the therapy into standard practice.

Main revenue and product drivers for Pulmonx Corp

Pulmonx’s revenue is closely tied to uptake of the Zephyr valve system, which has been approved in the United States and several international markets for specific emphysema patients. Expansion of treatment centers, physician training and reimbursement coverage in the US and Europe are key levers for growing procedure volumes and device sales.

Management has highlighted efforts to improve gross margin through manufacturing efficiencies and disciplined pricing, even as overall growth has slowed in recent quarters, according to the April 30, 2025 earnings summary from TipRanks as of 04/30/2025. These margin gains are important because Pulmonx is still investing in commercial infrastructure and clinical development.

Another driver is the company’s focus on physician education and support. Job postings for clinical education and medical training roles indicate that Pulmonx is investing in programs that help clinicians understand patient selection, procedure techniques and post-treatment care, based on a review of listings on Indeed dated 2025 from Indeed as of 2025. Such efforts can foster greater familiarity with the technology and ultimately support recurring procedure volumes.

Liquidity, credit facility and growth pause

While Pulmonx operates in a specialized niche with significant unmet medical need, the company is also facing what management has described as a growth pause, with more moderate revenue expansion compared with earlier periods, according to the April 30, 2025 call summary by TipRanks as of 04/30/2025. Factors can include procedure scheduling patterns, hospital capital constraints and reimbursement dynamics.

Against this backdrop, the reported 61.6 million USD in cash, cash equivalents and marketable securities, alongside a new 60 million USD interest-only credit facility, gives Pulmonx additional financial flexibility to navigate near-term volatility. The facility can help support ongoing R&D, sales infrastructure and working capital while the company works to reaccelerate growth, as highlighted in the same earnings recap by TipRanks as of 04/30/2025.

For US investors, balance sheet strength in a medtech name like Pulmonx can be particularly relevant because reimbursement approvals, clinical adoption curves and capital spending cycles can be unpredictable. Access to a committed credit line may reduce the risk of needing to raise equity capital under unfavorable market conditions if the growth pause persists longer than expected.

Industry trends and competitive position

Pulmonx operates in the broader respiratory care and minimally invasive intervention space, where device makers compete on clinical outcomes, safety profiles, ease of use and reimbursement support. For severe emphysema, treatment options include medical therapy, lung volume reduction surgery and lung transplantation, each with varying risk and eligibility profiles.

The company’s Zephyr valve system offers an option that sits between drug therapy and major surgery, aiming to provide meaningful lung volume reduction through a bronchoscopic procedure. Competing technologies and traditional surgical approaches may limit Pulmonx’s share in some markets, but validated clinical data and real-world outcomes are important differentiators when hospitals choose which interventions to support.

Broader trends such as aging populations, rising prevalence of chronic lung disease and heightened attention to respiratory health in the wake of global respiratory pandemics can sustain long-term demand for improved treatments. At the same time, reimbursement scrutiny and cost-effectiveness evaluations can influence how quickly new technologies like Zephyr valves can scale within public and private payer systems.

Why Pulmonx Corp matters for US investors

Pulmonx is listed on Nasdaq under the ticker LUNG, giving US investors direct exposure to a specialized medtech company targeting debilitating lung disease. The United States is one of the company’s most important markets due to its large COPD patient pool, advanced interventional pulmonology centers and established reimbursement frameworks.

For US-focused portfolios, Pulmonx represents a way to gain exposure to innovation in procedural lung care rather than pharmaceuticals. Adoption trends at US hospitals, updates to reimbursement policies and data from domestic clinical programs can all act as catalysts or risk factors for the stock. Changes in US healthcare spending, Medicare policies and hospital capital budgets may also have an outsized impact on the company’s trajectory compared with smaller international markets.

Conclusion

Pulmonx Corp finds itself at an interesting juncture: the company is benefiting from improving gross margins and enhanced liquidity, but is also contending with a period of slower growth in procedure volumes and revenue. Its minimally invasive approach to treating severe emphysema differentiates the business within the broader medtech landscape, while the Nasdaq listing ensures direct relevance for US investors. How effectively management can convert financial flexibility and physician education initiatives into renewed growth momentum, while navigating reimbursement and competitive pressures, will likely shape sentiment toward the stock over the coming quarters.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.